NO871267L - Fremgangsmaate for fremstilling av terapeutisk aktive tiazepinforbindelser. - Google Patents

Fremgangsmaate for fremstilling av terapeutisk aktive tiazepinforbindelser.

Info

Publication number
NO871267L
NO871267L NO871267A NO871267A NO871267L NO 871267 L NO871267 L NO 871267L NO 871267 A NO871267 A NO 871267A NO 871267 A NO871267 A NO 871267A NO 871267 L NO871267 L NO 871267L
Authority
NO
Norway
Prior art keywords
tiazepine
compounds
procedure
preparation
therapeutic active
Prior art date
Application number
NO871267A
Other languages
English (en)
Other versions
NO871267D0 (no
NO168771C (no
NO168771B (no
Inventor
Edward John Warawa
Bernard Martin Migler
Original Assignee
Ici America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595359&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO871267(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici America Inc filed Critical Ici America Inc
Publication of NO871267D0 publication Critical patent/NO871267D0/no
Publication of NO871267L publication Critical patent/NO871267L/no
Publication of NO168771B publication Critical patent/NO168771B/no
Publication of NO168771C publication Critical patent/NO168771C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO871267A 1986-03-27 1987-03-26 Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse 11-(4-(2-(2-hydroksyetoksy)etyl)-1-piperazinyl)dibenzo(b,f)-(1,4)-tiazepin og farmasoeytisk akseptable salter derav NO168771C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868607684A GB8607684D0 (en) 1986-03-27 1986-03-27 Thiazepine compounds

Publications (4)

Publication Number Publication Date
NO871267D0 NO871267D0 (no) 1987-03-26
NO871267L true NO871267L (no) 1987-09-28
NO168771B NO168771B (no) 1991-12-23
NO168771C NO168771C (no) 1992-04-01

Family

ID=10595359

Family Applications (2)

Application Number Title Priority Date Filing Date
NO871267A NO168771C (no) 1986-03-27 1987-03-26 Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse 11-(4-(2-(2-hydroksyetoksy)etyl)-1-piperazinyl)dibenzo(b,f)-(1,4)-tiazepin og farmasoeytisk akseptable salter derav
NO2001009C NO2001009I1 (no) 1986-03-27 2001-06-07 Kvetiapin og farmasøytisk akseptable salter derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2001009C NO2001009I1 (no) 1986-03-27 2001-06-07 Kvetiapin og farmasøytisk akseptable salter derav

Country Status (31)

Country Link
US (1) US4879288A (no)
EP (1) EP0240228B1 (no)
JP (1) JPH064606B2 (no)
KR (1) KR900001868B1 (no)
AR (1) AR242198A1 (no)
AT (1) ATE58132T1 (no)
AU (1) AU593336B2 (no)
BG (1) BG61365B2 (no)
CA (1) CA1288428C (no)
CY (2) CY1706A (no)
DD (1) DD259403A5 (no)
DE (3) DE10075016I2 (no)
DK (1) DK174618B1 (no)
ES (1) ES2019379T4 (no)
FI (1) FI86059C (no)
GB (2) GB8607684D0 (no)
GR (1) GR3001061T3 (no)
HK (1) HK85393A (no)
HU (1) HU201062B (no)
IE (1) IE59864B1 (no)
IL (1) IL81923A (no)
LU (1) LU90593I2 (no)
MW (1) MW2087A1 (no)
NL (1) NL980022I2 (no)
NO (2) NO168771C (no)
NZ (1) NZ219788A (no)
PH (1) PH26516A (no)
PT (1) PT84569B (no)
ZA (1) ZA871940B (no)
ZM (1) ZM2987A1 (no)
ZW (1) ZW5787A1 (no)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
DE3827447A1 (de) * 1988-08-12 1990-04-26 Basf Ag Polyazofarbstoffe und deren zwischenprodukte
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
GB9109557D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
CA2250042A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
GB9716161D0 (en) * 1997-08-01 1997-10-08 Zeneca Ltd Process
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
ES2275619T3 (es) * 2000-12-20 2007-06-16 Astrazeneca Ab Quetiapina para el tratamiento de discinesia en pacientes no psicoticos.
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
JP2004518699A (ja) * 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
PT1458888E (pt) * 2001-12-10 2011-06-01 Novartis Ag Métodos para tratar a psicose e a esquizofrenia baseados em polimorfismos no gene do cntf
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
IL164155A0 (en) * 2002-03-20 2005-12-18 Teva Pharma Crystalline forms of quetiapine hemifumarate
KR100707050B1 (ko) 2002-11-28 2007-04-13 에스케이 주식회사 10Ｈ-디벤조[ｂ,ｆ][1,4]티아제핀-11-온의 제조방법
ES2308136T3 (es) * 2003-01-14 2008-12-01 Gilead Sciences, Inc. Composiciones y procedimientos para la politerapia antiviral.
WO2004076431A1 (en) * 2003-02-22 2004-09-10 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof
US7238686B2 (en) * 2003-03-03 2007-07-03 Hetero Drugs Limited Polymorphs of quetiapine fumarate
EP1611138A1 (en) * 2003-04-07 2006-01-04 Hetero Drugs Limited A novel crystalline form of dorzolamide hydrochloride
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
CN1816339B (zh) * 2003-07-02 2010-12-15 阿斯利康(瑞典)有限公司 喹硫平的代谢物
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
ES2223294B2 (es) 2003-08-08 2005-10-01 Vita Cientifica, S.L. Procedimiento de preparacion de un compuesto farmaceuticamente activo.
US20050080072A1 (en) * 2003-09-01 2005-04-14 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of a thiazepine derivative
JP2007505865A (ja) * 2003-09-23 2007-03-15 フェルミオン オサケ ユキチュア クエチアピンの製造
CN101005829A (zh) * 2003-10-21 2007-07-25 艾克塔维斯集团公司 喹硫平制剂
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
SI1696931T1 (sl) 2003-12-22 2009-08-31 Acadia Pharm Inc Amino substituirani diaril(a,d)cikloheptenski analogi kot muskarinski agonisti in postopki za zdravljenje nevropsihiatričnih motenj
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR101038389B1 (ko) * 2004-06-23 2011-06-01 에스케이바이오팜 주식회사 11-(4-[2-(2-히드록시에톡시)에틸]-1-피페라지닐)-디벤조[ｂ,ｆ][1,4]티아제핀의 제조방법
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
AU2005277134A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
WO2006027789A1 (en) * 2004-09-08 2006-03-16 Jubilant Organosys Limited PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
US20060063927A1 (en) * 2004-09-22 2006-03-23 Olga Etlin Processes for preparing quetiapine and salts thereof
WO2006035293A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Polymorphic forms of quetiapine hemifumarate
WO2006056772A2 (en) * 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Salts of quetiapine
JP2008526839A (ja) * 2005-01-07 2008-07-24 アストラゼネカ・アクチエボラーグ １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
EP1841751A1 (en) * 2005-01-24 2007-10-10 IPCA Laboratories Limited INDUSTRIAL PREPARATION OF 11-(4-(2-(2-HYDROXYETHOXY ETHYL)-1-PIPERAZINYL)DIBENZO (b,f)-1(1, 4)THIAZEPINE
MX2007008985A (es) * 2005-01-26 2007-12-06 Elan Pharma Int Ltd Composiciones de liberacion controlada que comprenden un agente anti-sicotico.
ES2234447B1 (es) 2005-03-07 2006-03-01 Union Quimico-Farmaceutica S.A. Procedimiento para la obtencion de un derivado de 11-(4-sustituido-1-piperazinil)dibenzo(b,f)(1,4)tiazepina.
WO2006101745A2 (en) * 2005-03-18 2006-09-28 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
US7488821B2 (en) * 2005-04-04 2009-02-10 Divi's Laboratories Limited Polymorph of Quetiapine fumarate and a process for its preparation
CA2603795A1 (en) * 2005-04-14 2006-10-26 Teva Pharmaceutical Industries Ltd. Process for preparing quetiapine fumarate
AR053237A1 (es) 2005-04-21 2007-04-25 Medichem Sa Proceso para la preparacion de quetiapina y fumarato de quetiapina
PE20061318A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
JP2008545650A (ja) * 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US20070072840A1 (en) * 2005-05-30 2007-03-29 Pandya Bhargav Polymorphic forms of quetiapine
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
GB0516603D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Processes for the preparation of organic compounds useful as serotonin receptor antagonists
EP1928849A1 (en) 2005-09-30 2008-06-11 Fermion Oy New crystallization process of quetiapine hemifumarate
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
WO2008079839A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab Compounds and uses thereof
WO2009151392A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
WO2009151393A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
US8389510B2 (en) * 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
WO2007086079A2 (en) 2006-01-25 2007-08-02 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
WO2007102074A2 (en) * 2006-03-07 2007-09-13 Cadila Healthcare Limited Salts of quetiapine
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
ATE523602T1 (de) 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CZ300451B6 (cs) 2006-07-03 2009-05-20 Farmak, A. S. Zpusob prípravy solí 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanolu (quetiapinu) a jejich cištení
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
WO2008066620A2 (en) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives
CA2704279C (en) * 2006-11-03 2014-09-30 University Of Saskatchewan Method of treating demyelination diseases
EP2578216A1 (en) 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Methods of treating fragile x syndrome
EP2120563A4 (en) * 2006-12-20 2011-04-27 Astrazeneca Ab CONNECTIONS AND ITS USES
WO2008110337A2 (en) 2007-03-09 2008-09-18 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
CN100569761C (zh) * 2007-04-18 2009-12-16 湖南洞庭药业股份有限公司 制备药物纯富马酸喹硫平的生产方法
US8101597B2 (en) * 2007-05-07 2012-01-24 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
US20080287418A1 (en) 2007-05-16 2008-11-20 Astrazeneca Ab Extended Release Compositions and Methods for Their Manufacture
HU230144B1 (hu) * 2007-06-12 2015-09-28 Richter Gedeon Nyrt. Eljárás quetiapin előállítására
US20090082334A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched quetiapine
US20090220593A1 (en) * 2008-01-29 2009-09-03 Gulati Inder Extended release dosage forms of quetiapine
US8420807B2 (en) * 2008-01-31 2013-04-16 Fermion Oy Process for the preparation of quetiapine
EP2254420A4 (en) 2008-02-20 2012-02-15 Targia Pharmaceuticals CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090264408A1 (en) * 2008-04-17 2009-10-22 Gulati Inder Extended release dosage forms of quetiapine
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
ME01516B (me) * 2008-06-20 2014-04-20 Astrazeneca Ab DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA
NZ590682A (en) 2008-06-23 2012-09-28 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
WO2010001413A2 (en) * 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising quetiapine
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010011232A1 (en) * 2008-07-24 2010-01-28 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
EP2262486B1 (en) * 2008-08-01 2013-01-02 KRKA, Tovarna Zdravil, D.D., Novo Mesto Quetiapine composition
EP2153834A3 (en) 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
EP2340254B8 (en) 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
EP2373319B1 (en) * 2009-01-05 2013-07-31 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2403841A1 (en) 2009-03-04 2012-01-11 Ranbaxy Laboratories Limited Process for the preparation of quetiapine fumarate
EP2233130A1 (en) 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
US20110183963A1 (en) 2009-12-31 2011-07-28 Travis Mickle Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
FI3446565T3 (fi) 2010-08-23 2024-01-30 Alkermes Pharma Ireland Ltd Menetelmiä antipsykoottisten lääkkeiden aiheuttaman painonnousun hoitamiseksi
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
US8741888B2 (en) 2010-11-09 2014-06-03 Carl A. Forest Sleep aid composition and method
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
TR201104977A1 (tr) 2011-05-23 2012-12-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
WO2013074048A2 (en) 2011-08-08 2013-05-23 Mahmut Bilgic Tablet forms comprising quetiapine fumarate
CN102391208A (zh) * 2011-10-25 2012-03-28 湖南洞庭药业股份有限公司 富马酸喹硫平的新晶形i及其制备方法
WO2013095312A1 (en) 2011-12-19 2013-06-27 Mahmut Bilgic Formulations comprising quetiapine fumarate
WO2013100879A1 (en) 2011-12-27 2013-07-04 Mahmut Bilgic Pharmaceutical compositions comprising quetiapine
US20150018362A1 (en) 2012-02-27 2015-01-15 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
JP6883988B2 (ja) 2013-12-20 2021-06-09 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
CN104016945B (zh) * 2014-05-27 2016-06-29 渭南畅通药化科技有限公司 一种半富马酸喹硫平的制备方法
EA036844B1 (ru) 2015-06-19 2020-12-28 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7514534B2 (ja) 2018-06-19 2024-07-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
WO2020025579A1 (en) 2018-07-31 2020-02-06 Medichem, S.A. Solid dosage form of quetiapine fumarate
WO2022058989A1 (en) 2020-09-21 2022-03-24 Sun Pharmaceutical Industries Limited Multi-particulate pharmaceutical composition of quetiapine
CN113698363A (zh) * 2021-09-15 2021-11-26 苏州敬业医药化工有限公司 一种11-哌嗪-二苯并[b,f][1,4]硫氮杂卓盐酸盐的纯化方法
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3389139A (en) * 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
FR111F (no) * 1964-03-27
FR90378E (no) * 1965-03-26 1968-02-14
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CH539044A (de) * 1967-10-06 1973-08-31 Gnii Orch Poluproduktov I Kras Verfahren zur Herstellung quaternärer Ammoniumsalze von 1,3-Bis-(aminomethyl)-imidazolidonen
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
GB1262509A (en) * 1969-06-20 1972-02-02 Science Union & Cie New tricyclic derivatives and process for their preparation
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
BE792426A (fr) * 1971-12-09 1973-06-07 Wander Ag Dr A Nouveaux derives de la dibenzo(b,f)(1,4)thiazepine, leur preparation etleur application comme medicaments
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (no) * 1972-04-04 1975-11-28 Wander Ag Dr A
CH624682A5 (no) * 1976-11-10 1981-08-14 Sandoz Ag
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines

Also Published As

Publication number Publication date
NL980022I2 (nl) 1998-11-02
IE59864B1 (en) 1994-04-20
GB8706949D0 (en) 1987-04-29
HU201062B (en) 1990-09-28
ATE58132T1 (de) 1990-11-15
NO2001009I1 (no) 2001-06-25
LU90593I2 (fr) 2000-08-07
ES2019379B3 (es) 1991-06-16
ES2019379T4 (es) 2015-08-12
KR870008879A (ko) 1987-10-21
CY98045I1 (el) 2010-07-28
BG61365B2 (bg) 1997-06-30
KR900001868B1 (ko) 1990-03-26
CA1288428C (en) 1991-09-03
PT84569A (en) 1987-04-01
IL81923A (en) 1991-03-10
AU593336B2 (en) 1990-02-08
NO871267D0 (no) 1987-03-26
FI871137A (fi) 1987-09-28
EP0240228B1 (en) 1990-11-07
IL81923A0 (en) 1987-10-20
NO168771C (no) 1992-04-01
FI871137A0 (fi) 1987-03-16
FI86059B (fi) 1992-03-31
ZA871940B (en) 1987-11-25
ZW5787A1 (en) 1988-11-02
PT84569B (pt) 1989-11-30
EP0240228A1 (en) 1987-10-07
HK85393A (en) 1993-08-27
FI86059C (fi) 1992-07-10
NL980022I1 (nl) 1998-10-01
CY98045I2 (el) 2010-07-28
DK158587D0 (da) 1987-03-27
CY1706A (en) 1994-01-14
JPH064606B2 (ja) 1994-01-19
DK158587A (da) 1987-09-28
GB8607684D0 (en) 1986-04-30
NZ219788A (en) 1990-02-26
DE10075017I1 (de) 2000-09-21
US4879288A (en) 1989-11-07
PH26516A (en) 1992-08-07
IE870700L (en) 1987-09-27
GR3001061T3 (en) 1992-03-20
AR242198A1 (es) 1993-03-31
DE3765969D1 (en) 1990-12-13
DD259403A5 (de) 1988-08-24
DK174618B1 (da) 2003-07-21
HUT47568A (en) 1989-03-28
JPS638378A (ja) 1988-01-14
DE10075016I2 (de) 2002-10-10
ZM2987A1 (en) 1991-02-28
AU7045987A (en) 1987-10-01
NO168771B (no) 1991-12-23
MW2087A1 (en) 1987-11-11

Similar Documents

Publication Publication Date Title
NO871267L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiazepinforbindelser.
NO871266D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO871277D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive oxadiazoler.
NO870526D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater.
NO875082D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridinoksimer.
NO874869L (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO883974D0 (no) Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.
NO168174C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive triazolforbindelser
NO874032L (no) Fremgangsmaate for fremstilling av terapeutisk aktive catecholderivater.
NO864879L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiazolforbindelser.
NO871588D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske karboksamider.
NO862373D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tienopyridoner.
NO883485L (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinyl-isokinolinforbindelser.
NO875488D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
NO890155D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive indolpiperidin-forbindelser.
NO885598L (no) Fremgangsmaate for fremstilling av terapeutisk aktive ammoniumforbindelser.
NO880667D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylpiperazinyl-alkylen-fenyl-heterocykliske forbindelser.
NO861584L (no) Fremgangsmaate til fremstilling av terapeutisk aktive cyklopentyletere.
NO873680L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfonamido-etyl-forbindelser.
NO164899C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolylindolforbindelser.
NO873514D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk aktive forbindelser.
NO168247C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-metoksy-alkyl-ammonium-tetrahydrofuraner.
NO871907D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkenamid-derivater.
NO882281D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO883959L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenolestere.

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: KVETIAPIN OG FARMASOEYTISK AKSEPTABLE SALTER DERAV; NAT. REG. NO/DATE: NO , 96-2448, NO , 96-2450, NO , 96-2451 20001221

Spc suppl protection certif: 2001009

Filing date: 20010607

Extension date: 20120326

SPCX Expiry of an spc

Spc suppl protection certif: 2001009

Effective date: 20120326